ES2187830T3 - Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad. - Google Patents

Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad.

Info

Publication number
ES2187830T3
ES2187830T3 ES97946043T ES97946043T ES2187830T3 ES 2187830 T3 ES2187830 T3 ES 2187830T3 ES 97946043 T ES97946043 T ES 97946043T ES 97946043 T ES97946043 T ES 97946043T ES 2187830 T3 ES2187830 T3 ES 2187830T3
Authority
ES
Spain
Prior art keywords
obesity
treatment
neurotrophic factor
iar
cil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97946043T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Patrizia Costa
Giacomo Paonessa
Domenico Lazzaro
Isabelle Gloaguen
Marco Annalise Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Application granted granted Critical
Publication of ES2187830T3 publication Critical patent/ES2187830T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DEL HCNTF (FACTOR NEUROTROFICO CILIAR HUMANO), DE ALGUNOS DE SUS MUTANTES, O DE OTRAS MOLECULAS QUE ACTIVAN EL RECEPTOR DEL CNTF, PARA LA ELABORACION DE MEDICAMENTOS DESTINADOS AL TRATAMIENTO DE LA OBESIDAD Y DE SUS ENFERMEDADES ASOCIADAS COMO POR EJEMPLO, LA HIPERGLICEMIA. LA FIGURA 1 ILUSTRA LA EFICACIA ANTIOBESIDAD DEL HCNTF Y LA EFICACIA DE LA LEPTINA SOBRE LA MASA CORPORAL (CUADROS DE LA IZQUIERDA) Y SOBRE LA RACION DE ALIMENTOS (CUADROS DE LA DERECHA) EN RATONES GENETICAMENTE OBESOS Y SOBRE RATONES DE OBESIDAD INDUCIDA POR EL REGIMEN ALIMENTICIO (DIO).
ES97946043T 1996-11-19 1997-11-18 Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad. Expired - Lifetime ES2187830T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Publications (1)

Publication Number Publication Date
ES2187830T3 true ES2187830T3 (es) 2003-06-16

Family

ID=11404538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97946043T Expired - Lifetime ES2187830T3 (es) 1996-11-19 1997-11-18 Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad.

Country Status (14)

Country Link
US (2) US6565869B1 (es)
EP (1) EP0946189B1 (es)
JP (1) JP4067127B2 (es)
CN (2) CN102145163B (es)
AT (1) ATE228003T1 (es)
AU (1) AU727174B2 (es)
CA (1) CA2271781C (es)
DE (1) DE69717308T2 (es)
DK (1) DK0946189T3 (es)
ES (1) ES2187830T3 (es)
IL (2) IL129968A0 (es)
IT (1) IT1288388B1 (es)
PT (1) PT946189E (es)
WO (1) WO1998022128A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU718500B2 (en) * 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
IT1291114B1 (it) 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6680291B1 (en) 1998-02-27 2004-01-20 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
PT1165613E (pt) 1999-03-29 2008-07-29 Procter & Gamble Ligantes do receptor de melanocortina
AU4651900A (en) * 1999-04-20 2000-11-02 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
AU2001230587A1 (en) * 2000-02-18 2001-08-27 Sumitomo Pharmaceuticals Company, Limited Drugs for ameliorating impaired glucose tolerance
EP1262189A1 (en) * 2000-03-06 2002-12-04 Sumitomo Pharmaceuticals Company, Limited Leptin-resistance ameliorating agents
WO2001089550A2 (en) * 2000-05-24 2001-11-29 Regeneron Pharmaceuticals, Inc. Use of ciliary neurotrophic factor
EP1290206A2 (en) * 2000-06-09 2003-03-12 University of Florida Recombinant aav vectors for gene therapy of obesity
HUP0303310A2 (hu) * 2001-03-02 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7279282B2 (en) * 2004-07-09 2007-10-09 Scott Mellis Methods for identifying a candidate for treatment of obesity
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104558148B (zh) * 2013-10-17 2018-11-06 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和用途
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
CN107073077B (zh) * 2014-11-07 2020-12-01 陕西麦科奥特科技有限公司 睫状神经营养因子鼻腔给药系统及其制备方法和应用
CN106632650B (zh) * 2015-10-30 2020-11-13 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和应用
CA3038185A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US11179441B2 (en) 2017-01-06 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
JP2021531328A (ja) * 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ−α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン−アスパラギン酸プロテアーゼを含む薬剤送達系
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
CA3162324A1 (en) * 2019-12-18 2021-06-24 Rhett M. Schiffman Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-.alpha. (tnf-.alpha.) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
US5426177A (en) 1990-06-01 1995-06-20 Regeneron Pharmaceuticals, Inc. Ciliary neurotrophic factor receptor
CS156891A3 (en) 1990-06-01 1992-04-15 Regeneron Pharma Receptor of a cilary neurotropic factor
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
WO1993002206A1 (en) 1991-07-23 1993-02-04 Syntex-Synergen Neuroscience Joint Venture Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage
US5691313A (en) 1991-07-23 1997-11-25 Amgen Inc. Methods of treating impotency with ciliary neurotrophic factor
US5593857A (en) 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1993010233A1 (en) 1991-11-11 1993-05-27 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
US5955290A (en) 1991-12-02 1999-09-21 Regeneron Pharmaceuticals, Inc. Assay systems using the CNTF signal transduction pathway
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
IT1284867B1 (it) * 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Also Published As

Publication number Publication date
US6960558B2 (en) 2005-11-01
AU727174B2 (en) 2000-12-07
EP0946189A1 (en) 1999-10-06
CN101703761B (zh) 2013-11-20
DE69717308T2 (de) 2003-07-10
WO1998022128A1 (en) 1998-05-28
IL129968A (en) 2005-11-20
DE69717308D1 (de) 2003-01-02
PT946189E (pt) 2003-02-28
CA2271781A1 (en) 1998-05-28
IT1288388B1 (it) 1998-09-22
ITRM960790A0 (it) 1996-11-19
IL129968A0 (en) 2000-02-29
CA2271781C (en) 2002-11-12
JP2000511561A (ja) 2000-09-05
US6565869B1 (en) 2003-05-20
EP0946189B1 (en) 2002-11-20
CN101703761A (zh) 2010-05-12
DK0946189T3 (da) 2002-12-16
CN102145163A (zh) 2011-08-10
JP4067127B2 (ja) 2008-03-26
US20030176346A1 (en) 2003-09-18
ITRM960790A1 (it) 1998-05-19
AU5134498A (en) 1998-06-10
CN102145163B (zh) 2013-09-18
ATE228003T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
ES2187830T3 (es) Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad.
CL2004000674A1 (es) Sistema terapeutico transdermico que comprende al menos una sustancia activa farmaceutica, al menos un disruptor de la estructura y/o al menos un formador de estructura en una matriz comun.
NO180567C (no) Befruktningshindrende og/eller syklusregulerende middel for transdermal applikasjon
MY108638A (en) Antiviral nucleoside combination.
ISE et al. Effect of Far-Infrared Radiation on Forearm Skin Bloodd Flow
DE69228997D1 (de) Menschliche il-3-varianten
ES2144817T3 (es) Bandeja para huevos.
Caplan Population-oriented psychiatry.
GT199900066A (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea.
ES2159357T3 (es) Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales.
ES2068388T3 (es) Moleculas de receptor de hormona de la glucoproteina.
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
Rustum et al. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
Omark Diffusion of a mental health ideology.
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
NO895009L (no) Ergonomisk pute, saerlig for beskyttelse og/eller behandling av nakken.
Smirnova MI Lisina's communication concept and its significance for Russian psychology
AR036846A1 (es) Aplicacion terpeutica de agonistas selectivos del estrogenorreceptor beta (erbeta) para provocar efectos somatotropos, organotropos y anticatabolicos
TR199901998T2 (xx) 9,10-sekokolesta-5,7,10(19)-triyen-1,3-diyol veya alfakasidol�n kullan�m�.
Ono et al. IN VITRO DRUG METABOLISM BY A HUMAN P450 EXPRESSION SYSTEM USING VACCINIA VIRUS.
Rubio The Internalization of an Ideal Body into the Self: Psychological, Emotional, and Physical Consequences
竹晨 Light and Health From VOA Science in the News
Faruqui Whiter NICVD